More good news about the twice-yearly PrEP injection
rare result for any clinical trial. In that instance, researchers studied over 2,000 young women in South Africa and Uganda.
Both countries have high infection rates.Subscribe to our newsletter for a refreshing cocktail (or mocktail) of LGBTQ+ entertainment and pop culture, served up with a side of eye-candy.At present, current forms of PrEP don’t work as well in women as they do in men.
This is because the medication’s efficiency is tied to maintaining a sufficient concentration in crucial body tissues. For example, higher concentrations of Truvada accumulate in rectal tissue compared to the vagina.Yesterday, Gilead released further data at the 5th HIV Research for Prevention Conference (HIVR4P) in Lima, Peru.Its latest trial included 2,180 gay and queer men, and trans individuals, who have sex with men.
It found that lenacapavir reduced HIV infections by 96%. Of the 2,180 participants, 99.9% did not acquire HIV. Two individuals did so.This is a better result than those who take a daily PrEP pill.
